Finding: Proteinuria

Medical news and research articles

FDA approves Empaveli for rare kidney diseases

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

page 1 from 3